Nociceptin-based analgesics

Details Nociceptin-based analgesics Nociceptin-based analgesics

2006-05-23

2006-05-23

Tate, Christopher R. (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

Reexamination Certificate

active

07049287

ABSTRACT:
The invention relates to a family of hexapeptide compounds exhibiting activity with regard to the ORL-1 receptor. The compounds share a general formula of Arg-Tyr-Tyr-Arg-Trp-Arg, and may be constructed having modifications or substitutions at any position, and may include modifications of the amino- and carboxy-termini of the hexapeptide. These compounds include agents exhibiting agonist activity and antagonist activity when exposed to the human ORL-1 receptor. As such, the hexapeptides may be useful as analgesics, anxiolytics, diuretics, and anti-cancer agents.

REFERENCES:
patent: 5821219 (1998-10-01), Grandy et al.
patent: 6011006 (2000-01-01), Thomsen et al.
patent: 2001/0011092 (2001-08-01), Tulshian et al.
patent: 1072263 (2001-01-01), None
patent: WO - 99/44627 (1999-09-01), None
patent: WO - 01/98324 (2001-12-01), None
Minks, et al., Towards New Protein Engineering: In Vivo Building and Folding of Protein Shuttles for Drug Delivery and Targeting by the Selective Pressure Incorporation (SPI) Method, Tetrahedron, 2000, vol. 56, pp. 9431-9442.
Encyclopedia Britannica, http://www.search.eb.com/eb/article?tocid=233942, Nov. 8, 2004.
Wikipedia, http://en.wikipedia.org/wiki/analgesic, Oct. 6, 2004.
On-line Medical Dictionary, Nov. 18, 1997, http://cancerweb.ncl.ac.uk./cgi-bin.omd?modify.
Calo, Girolamo, et al., “Pharmacological Profile of Nociceptin/Orphanin FQ Receptors,” Clinical and Experimental Pharmacology and Physiology, 29, 2002, 223-28.
Dooley, Colette T., et al., “Binding and In Vitro Activities of Peptides with High Affinity For The Nociceptin/Orphanin FQ Receptor, ORL1,” The Journal of Pharmacology and Experimental Therapeutics, 283, 2, 735-741, 1997.
Kawamoto, Hiroshi, et al., “Discovery of the First Potent and Selective Small Molecule Opioid Receptor-like (ORL1) Antagonish 1-[(3R, 4R) -1-Cyclooctylmethyl-3-hydroxymethyl-4-piperidyl}-3-ethyl-1,3-dihydro-2h-benimidazol-2-one (J-113397),” Journal of Medicinal Chemistry, 42, 25, 5061-63, 1999.
Khroyan, T.V., et al., “High Affinity Hexapeptides for ORL1 Receptors: In Vitro Activity and In Vivo Nociceptive Effects.”.
Thomsen, Christian, et al., “[3H]ac-RYYRWK-HN2, A Novel Specific Radioligand for the Nociceptin/Orphanin FQ Receptor,” Naunyn-Schmiedeberg's Arch Pharmacol (2000) 362, 538-545.
“Characterization of the ORL1Receptor on Adrenergic Nerves in the Rat Anococcygeus Muscle,” Corbett et al.,British Journal of Pharmacology, pp. 349-355, 2000.
“Potent Orphanin FQ Receptor Ligands Identified Using Combinatorial Libraries,” Dooley et al.,The European Peptide Society, pp. 343-344, 1998.

Affiliated with

Also associated with

Rating

Nociceptin-based analgesics does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Nociceptin-based analgesics, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nociceptin-based analgesics will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3555240